Stocktoria

Silence Therapeutics plc SLN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2010-01-05 · LEI

Silence Therapeutics plc statistics & valuation

Market cap$472.3M
P / B7.6×
Net margin-15851.9%
Return on equity-142.2%
FCF margin-11149.6%
Return on capital-77.3%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
-171.40% -104.70% -15851.90% 202320242025
Gross margin (%)
59.30% 72.70% 61.50% 202320242025
Operating margin (%)
-203.50% -146.40% -16292.80% 202320242025
Return on equity (%)
-246.60% -33.80% -142.20% 202320242025
Shares outstanding
118.8M 141.7M 141.7M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-45.40% -22.40% -67.40% 202320242025
Free cash flow margin (%)
-156.50% -156.90% -11149.60% 202320242025
Debt / equity (×)
202320242025
EPS ($)
-$0.49 -$0.33 -$0.63 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Gross margin61.5%72.7%59.3%
Operating margin-16292.8%-146.4%-203.5%
Net margin-15851.9%-104.7%-171.4%
FCF margin-11149.6%-156.9%-156.5%
Return on assets-67.4%-22.4%-45.4%
Return on equity-142.2%-33.8%-246.6%
Current ratio8.7211.144.62

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.